Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

- Daud, Adil I, Wolchok, Jedd D., Joseph, Richard, Gangadhar, Tara C., Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K., Li, Xiaoyun Nicole, Emancipator, Kenneth, Robert, Caroline, Dolled-Filhart, Marisa, Kang, S. Peter, Ebbinghaus, Scot, Hamid, Omid, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

- Hauschild, Axel, Agarwala, Sanjiv S, Peschel, Christian, Schadendorf, Dirk, Garbe, Claus, O'Day, Steven, Daud, Adil, White, J. Michael, Xia, Chenghua, Patel, Kiran, Kirkwood, John M., Keilholz, Ulrich, Trefzer, Uwe, Hogg, David, Robert, Caroline, Hersey, Peter, Eggermont, Alexander, Grabbe, Stephan, Gonzalez, Rene, Gille, Jens

EZH2 as a mediator of treatment resistance in melanoma

- Tiffen, Jessamy C., Gallagher, Stuart J., Tseng, Hsin-Yi, Filipp, Fabian V., Fazekas de St Groth, Barbara, Hersey, Peter

The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells

- Tseng, Hsin-Yi, Chen, Li Hua, Ye, Yan, Tay, Kwang Hong, Jiang, Chen Chen, Guo, Su Tang, Jin, Lei, Hersey, Peter, Zhang, Xu Dong

Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors

- Lai, Fritz, Jiang, Chen Chen, Farrelly, Margaret L., Zhang, Xu Dong, Hersey, Peter

Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21

- Shafren, Darren R., Au, Gough G., Nguyen, Tam, Hansbro, Nicole G., Haley, Erin S., Beagley, Leone, Johansson, Susanne E., Hersey, Peter, Barry, Richard D.

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma

- Eisen, Tim, Trefzer, Uwe, Hamilton, Anne, Hersey, Peter, Millward, Michael, Knight, Robert D., Jungnelius, Jarl U., Glaspy, John

Contrasting effects of Nutlin-3 on TRAIL- and Docetaxel-induced Apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells

- Tseng, Hsin-Yi, Jiang, Chen Chen, Croft, Amanda, Thorne, Rick Francis, Yang, Fan, Liu, Hao, Hersey, Peter, Zhang, Xu Dong

Targeting apoptotic pathways in melanoma

- Hersey, Peter, Zhang, Xu Dong

Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors

- Lai, Fritz, Jin, Lei, Gallagher, Stuart, Mijatov, Branka, Zhang, Xu Dong, Hersey, Peter

Involvement of endoplasmic reticulum stress in docetaxel-induced JNK-dependent apoptosis of human melanoma

- Mhaidat, Nizar M., Thorne, Rick, Zhang, Xu Dong, Hersey, Peter

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma

- Hamid, Omid, Robert, Caroline, Dronca, Roxana, Gangadhar, Tara C., Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M., Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Daud, Adil, Tumeh, Paul C., Chmielowski, Bartosz, Ebbinghaus, Scot W., Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D., Hersey, Peter, Joseph, Richard W., Weber, Jeffrey S.

Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

- Ribas, Antoni, Hamid, Omid, Gangadhar, Tara C., Hersey, Peter, Dronca, Roxana, Joseph, Richard W., Zarour, Hassane, Chmielowski, Bartosz, Lawrence, Donald P., Algazi, Alain, Rizvi, Naiyer A., Hoffner, Brianna, Daud, Adil, Mateus, Christine, Gergich, Kevin, Lindia, Jill A., Giannotti, Maxine, Li, Xiaoyun Nicole, Ebbinghaus, Scott, Kang, S. Peter, Robert, Caroline, Hodi, F. Stephen, Wolchok, Jedd D., Kefford, Richard, Joshua, Anthony M., Patnaik, Amita, Hwu, Wen-Jen, Weber, Jeffrey S.

Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab

- Hodi, F. Stephen, Hwu, Wen-Jen, Joshua, Anthony M., Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S. Peter, Ebbinghaus, Scot, Perrone, Andrea, Kefford, Richard, Wolchok, Jedd D., Weber, Jeffrey S., Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C.

Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737

- Lucas, Keryn M., Mohana-Kumaran, Nethia, Lau, Diana, Zhang, Xu Dong, Hersey, Peter, Huang, David C., Weninger, Wolfgang, Haass, Nikolas K., Allen, John D.

Overcoming resistance to apoptosis in cancer therapy

- Hersey, Peter, Zhang, Xu Dong, Mhaidat, Nizar

Side effects and toxicities of targeted therapies in stage IV melanoma

- Ascierto, Paolo A., Bastholt, Lars, Hersey, Peter, Cinat, Gabriela, Eggermont, Alexander M. M., Hauschild, Axel, Espinosa, Enrique, Robert, Caroline

Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells

- Zhang, Xi Yi, Zhang, Xu Dong, Borrow, Jodie M., Nguyen, Tam, Hersey, Peter

Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma

- Zhuang, Liquing, Scolyer, Richard A., Lee, C. Soon, McCarthy, Stanley W., Cooper, Wendy A., Zhang, Xu Dong, Thompson, John F., Hersey, Peter

Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax

- Jiang, Chen Chen, Wroblewski, David, Yang, Fan, Hersey, Peter, Zhang, Xu Dong